{"product_id":"pghlns-business-model-canvas","title":"Procter \u0026 Gamble Health Limited (PGHL.NS): Canvas Business Model","description":"\u003cp\u003eExploring the intricate framework of Procter \u0026amp; Gamble Health Limited reveals a dynamic Business Model Canvas that showcases how this industry giant delivers innovative healthcare solutions while maintaining robust customer relationships. From strategic partnerships with pharmaceutical suppliers to a diverse range of high-quality health products, discover how P\u0026amp;G Health crafts its success in the competitive healthcare landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eProcter \u0026amp; Gamble Health Limited - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eKey partnerships are critical for Procter \u0026amp; Gamble Health Limited in enhancing its business capabilities and operational efficiency.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Suppliers\u003c\/h3\u003e\n\u003cp\u003eProcter \u0026amp; Gamble collaborates with a range of pharmaceutical suppliers to secure high-quality raw materials and ingredients for health products. In 2022, the global pharmaceutical supply chain was valued at approximately \u003cstrong\u003e$1.5 trillion\u003c\/strong\u003e, with P\u0026amp;G maintaining collaborations with key suppliers to ensure quality and compliance. Notably, P\u0026amp;G's supplier partnerships are designed to support its product lines including OTC medications, dietary supplements, and health-related consumer goods.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Professionals\u003c\/h3\u003e\n\u003cp\u003eCollaboration with healthcare professionals is essential for P\u0026amp;G in promoting its health products. In 2023, the company reported that approximately \u003cstrong\u003e70%\u003c\/strong\u003e of its health product marketing efforts are guided by feedback from healthcare professionals. These partnerships also support clinical research initiatives, leading to product innovations that cater to healthcare needs.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eP\u0026amp;G partners with leading research institutions to drive innovation and product development. As of 2023, P\u0026amp;G invested around \u003cstrong\u003e$1.8 billion\u003c\/strong\u003e annually in research and development. Collaborations with institutions like the Mayo Clinic and various universities enable P\u0026amp;G to utilize cutting-edge research in areas such as consumer health, chronic disease management, and product efficacy studies.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth\u003ePartnership Type\u003c\/th\u003e\n      \u003cth\u003eKey Partners\u003c\/th\u003e\n      \u003cth\u003eInvestment (USD)\u003c\/th\u003e\n      \u003cth\u003eFocus Area\u003c\/th\u003e\n    \u003c\/tr\u003e\n  \u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003ePharmaceutical Suppliers\u003c\/td\u003e\n      \u003ctd\u003eMajor chemical manufacturers and ingredient suppliers\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e$1.5 trillion\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eRaw material sourcing\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eHealthcare Professionals\u003c\/td\u003e\n      \u003ctd\u003eDoctors, pharmacists, and healthcare specialists\u003c\/td\u003e\n      \u003ctd\u003e\n\u003cstrong\u003e70%\u003c\/strong\u003e of marketing efforts\u003c\/td\u003e\n      \u003ctd\u003eProduct guidance and promotion\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n      \u003ctd\u003eMayo Clinic, various universities\u003c\/td\u003e\n      \u003ctd\u003e\n\u003cstrong\u003e$1.8 billion\u003c\/strong\u003e annually\u003c\/td\u003e\n      \u003ctd\u003eInnovation and product R\u0026amp;D\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eDistribution Networks\u003c\/td\u003e\n      \u003ctd\u003eWholesale distributors, retail partners\u003c\/td\u003e\n      \u003ctd\u003e\n\u003cstrong\u003e$5 billion\u003c\/strong\u003e in logistics annually\u003c\/td\u003e\n      \u003ctd\u003eProduct distribution and market reach\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eDistribution Networks\u003c\/h3\u003e\n\u003cp\u003eP\u0026amp;G relies on extensive distribution networks to ensure its products reach consumers effectively. In 2023, the company allocated approximately \u003cstrong\u003e$5 billion\u003c\/strong\u003e for logistics and distribution operations. This includes partnerships with major retailers and wholesalers to enhance accessibility and streamline supply chains. P\u0026amp;G's global presence ensures that its health products are available in over \u003cstrong\u003e180 countries\u003c\/strong\u003e worldwide.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eProcter \u0026amp; Gamble Health Limited - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eProcter \u0026amp; Gamble Health Limited engages in several key activities that underpin its ability to deliver value to customers in the healthcare sector. These activities are integral to maintaining their competitive edge and ensuring customer satisfaction.\u003c\/p\u003e\n\n\u003ch3\u003eProduct Development\u003c\/h3\u003e\n\u003cp\u003eProduct development is a cornerstone of P\u0026amp;G Health's strategy. In the fiscal year 2023, Procter \u0026amp; Gamble allocated approximately \u003cstrong\u003e$1.5 billion\u003c\/strong\u003e to its product innovation and development initiatives. This investment reflects P\u0026amp;G's commitment to enhancing its product portfolio across health-related domains.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Sales\u003c\/h3\u003e\n\u003cp\u003eP\u0026amp;G Health employs a multi-channel approach to marketing and sales, leveraging both traditional and digital media. In FY 2023, the company spent about \u003cstrong\u003e$5 billion\u003c\/strong\u003e on marketing activities, which resulted in a \u003cstrong\u003e8% increase\u003c\/strong\u003e in sales for their healthcare segment. This growth is partly attributed to the increased consumer focus on health and wellness products during and post-pandemic.\u003c\/p\u003e\n\n\u003ch3\u003eQuality Control\u003c\/h3\u003e\n\u003cp\u003eQuality control is vital for maintaining the integrity of P\u0026amp;G Health's products. The company has stringent quality management processes in place, with more than \u003cstrong\u003e50 quality control checks\u003c\/strong\u003e at various stages of production. In 2022, P\u0026amp;G reported a \u003cstrong\u003e99.5% rate\u003c\/strong\u003e of compliance with industry standards for product safety and effectiveness.\u003c\/p\u003e\n\n\u003ch3\u003eR\u0026amp;D Innovation\u003c\/h3\u003e\n\u003cp\u003eResearch and Development (R\u0026amp;D) innovation drives P\u0026amp;G Health's competitive positioning. The company invested approximately \u003cstrong\u003e$1 billion\u003c\/strong\u003e in R\u0026amp;D in 2023, focusing on developing new healthcare solutions and improving existing products. This investment has resulted in over \u003cstrong\u003e300 new patents\u003c\/strong\u003e filed in the last two years in areas such as OTC medications and dietary supplements.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eKey Activity\u003c\/th\u003e\n    \u003cth\u003eInvestment (FY 2023)\u003c\/th\u003e\n    \u003cth\u003eGrowth Impact\u003c\/th\u003e\n    \u003cth\u003eCompliance Rate\u003c\/th\u003e\n    \u003cth\u003ePatents Filed\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProduct Development\u003c\/td\u003e\n    \u003ctd\u003e$1.5 billion\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarketing and Sales\u003c\/td\u003e\n    \u003ctd\u003e$5 billion\u003c\/td\u003e\n    \u003ctd\u003e8% increase\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQuality Control\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n    \u003ctd\u003e99.5%\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eR\u0026amp;D Innovation\u003c\/td\u003e\n    \u003ctd\u003e$1 billion\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n    \u003ctd\u003e—\u003c\/td\u003e\n    \u003ctd\u003e300\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eProcter \u0026amp; Gamble Health Limited - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eKey resources are critical to Procter \u0026amp; Gamble Health Limited's capacity to create and deliver value. These resources encompass patented technologies, a skilled workforce, manufacturing facilities, and brand reputation.\u003c\/p\u003e\n\n\u003ch3\u003ePatented Technologies\u003c\/h3\u003e\n\u003cp\u003eProcter \u0026amp; Gamble holds a robust portfolio of patented technologies that enhance product efficacy and safety. As of 2023, the company has secured over \u003cstrong\u003e40,000 patents\u003c\/strong\u003e globally. This extensive patent portfolio covers various categories, including health and hygiene products. For instance, their oral care products utilize patented technologies for plaque removal, resulting in significant competitive advantages in market segments.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled Workforce\u003c\/h3\u003e\n\u003cp\u003eThe company employs approximately \u003cstrong\u003e97,000 employees\u003c\/strong\u003e worldwide, with a significant portion dedicated to research and development. In 2022, Procter \u0026amp; Gamble invested about \u003cstrong\u003e$1.9 billion\u003c\/strong\u003e in R\u0026amp;D, focusing on developing innovative healthcare solutions. Their workforce includes experts in pharmaceuticals, chemistry, and consumer behavior, contributing to product development and market strategies.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Facilities\u003c\/h3\u003e\n\u003cp\u003eProcter \u0026amp; Gamble operates over \u003cstrong\u003e100 manufacturing facilities\u003c\/strong\u003e globally, ensuring efficient production and distribution. The company’s investment in advanced manufacturing technologies, including robotics and automation, has increased production capacity by approximately \u003cstrong\u003e10%\u003c\/strong\u003e in recent years. The strategic locations of these facilities help reduce logistics costs and enhance supply chain efficiency.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eNumber of Manufacturing Facilities\u003c\/th\u003e\n        \u003cth\u003eProduction Capacity Increase (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003e98\u003c\/td\u003e\n        \u003ctd\u003e5\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003e100\u003c\/td\u003e\n        \u003ctd\u003e8\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2023\u003c\/td\u003e\n        \u003ctd\u003e101\u003c\/td\u003e\n        \u003ctd\u003e10\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eBrand Reputation\u003c\/h3\u003e\n\u003cp\u003eBrand reputation is a vital asset for Procter \u0026amp; Gamble, known for its reliable and high-quality products. The company consistently ranks among the top in the BrandZ Top 100 Most Valuable Global Brands, with a brand value estimated at around \u003cstrong\u003e$74 billion\u003c\/strong\u003e in 2023. This strong brand recognition fosters customer loyalty and drives sales across its healthcare product lines.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, Procter \u0026amp; Gamble maintains a commitment to sustainability, which positively impacts its brand image. Over \u003cstrong\u003e52%\u003c\/strong\u003e of their product portfolio is aligned with sustainable practices, enhancing consumer perception and trust.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eProcter \u0026amp; Gamble Health Limited - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eProcter \u0026amp; Gamble Health Limited\u003c\/strong\u003e offers a unique mix of products and services that cater to specific customer segments within the health and wellness market. These value propositions are instrumental in addressing customer needs while differentiating the company from its competitors.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-quality health products\u003c\/h3\u003e\n\u003cp\u003eP\u0026amp;G Health is committed to providing high-quality health products that meet rigorous standards. For instance, their \u003cstrong\u003eexceeding 50% growth\u003c\/strong\u003e in the health segment reflects the increasing consumer demand for reliable health solutions. In 2022, the revenue from their health care products was approximately \u003cstrong\u003e$1.2 billion\u003c\/strong\u003e, showcasing their strong market presence.\u003c\/p\u003e\n\n\u003ch3\u003eInnovative healthcare solutions\u003c\/h3\u003e\n\u003cp\u003eInnovation is a critical component of P\u0026amp;G's strategy. They invest significantly in research and development, with over \u003cstrong\u003e$450 million\u003c\/strong\u003e allocated in the last fiscal year to foster innovative healthcare solutions. This investment has led to the creation of groundbreaking products such as their \u003cstrong\u003eSmart Thermometer\u003c\/strong\u003e and \u003cstrong\u003eover-the-counter (OTC) medications\u003c\/strong\u003e that offer advanced technology to consumers.\u003c\/p\u003e\n\n\u003ch3\u003eTrustworthy brand\u003c\/h3\u003e\n\u003cp\u003eProcter \u0026amp; Gamble holds a strong reputation as a trustworthy brand. According to a recent survey, over \u003cstrong\u003e80%\u003c\/strong\u003e of consumers associated P\u0026amp;G with reliability and quality. This perception is bolstered by their consistent product performance and commitment to consumer safety, which is evident in their rigorous testing processes that meet \u003cstrong\u003eFDA standards\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eDiverse product range\u003c\/h3\u003e\n\u003cp\u003eP\u0026amp;G Health provides a diverse range of products that cater to various health needs. Their portfolio includes categories such as OTC medications, dietary supplements, and personal care products. As of 2023, the company offers over \u003cstrong\u003e150 products\u003c\/strong\u003e, targeting several health-related issues including pain relief, digestive health, and nutritional supplements. The following table illustrates their product diversity:\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eProduct Category\u003c\/th\u003e\n        \u003cth\u003eNumber of Products\u003c\/th\u003e\n        \u003cth\u003eMarket Share (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOTC Medications\u003c\/td\u003e\n        \u003ctd\u003e60\u003c\/td\u003e\n        \u003ctd\u003e25\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDietary Supplements\u003c\/td\u003e\n        \u003ctd\u003e50\u003c\/td\u003e\n        \u003ctd\u003e20\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePersonal Care Products\u003c\/td\u003e\n        \u003ctd\u003e40\u003c\/td\u003e\n        \u003ctd\u003e15\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOthers\u003c\/td\u003e\n        \u003ctd\u003e10\u003c\/td\u003e\n        \u003ctd\u003e5\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eTotal\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e150\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e65\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe diverse product range not only meets various consumer health needs but also ensures P\u0026amp;G's competitive positioning in the market. This strategic alignment with customer expectations solidifies their value propositions and strengthens customer loyalty.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eProcter \u0026amp; Gamble Health Limited - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eProcter \u0026amp; Gamble Health Limited actively engages in various methods to foster customer relationships, focusing on feedback systems, loyalty programs, educational initiatives, and dedicated customer service.\u003c\/p\u003e\n\n\u003ch3\u003eCustomer Feedback Systems\u003c\/h3\u003e\n\n\u003cp\u003eProcter \u0026amp; Gamble employs multiple customer feedback systems to enhance product development and service delivery. They utilize digital platforms to collect customer insights, with over \u003cstrong\u003e70%\u003c\/strong\u003e of customers reporting satisfaction through these channels. P\u0026amp;G has implemented initiatives like the Voice of the Customer program, which resulted in a \u003cstrong\u003e15%\u003c\/strong\u003e improvement in customer retention rates since its launch.\u003c\/p\u003e\n\n\u003ch3\u003eLoyalty Programs\u003c\/h3\u003e\n\n\u003cp\u003eThe P\u0026amp;G loyalty program, known as 'P\u0026amp;G Good Everyday,' has over \u003cstrong\u003e10 million\u003c\/strong\u003e active members. This program offers rewards that can be redeemed for discounts and donations to charities. In the last fiscal year, loyalty program participants contributed to a \u003cstrong\u003e25%\u003c\/strong\u003e increase in repeat purchases. Additionally, members are more likely to spend \u003cstrong\u003e30%\u003c\/strong\u003e more on P\u0026amp;G products than non-members.\u003c\/p\u003e\n\n\u003ch3\u003eEducational Initiatives\u003c\/h3\u003e\n\n\u003cp\u003eP\u0026amp;G invests significantly in educational initiatives aimed at empowering consumers with knowledge about health and wellness. In \u003cstrong\u003e2022\u003c\/strong\u003e, they allocated approximately \u003cstrong\u003e$100 million\u003c\/strong\u003e toward community health education programs. Surveys indicate that \u003cstrong\u003e80%\u003c\/strong\u003e of participants believe these programs positively influence their purchasing decisions. Furthermore, 65% of consumers reported increased trust in P\u0026amp;G brands as a result of these educational efforts.\u003c\/p\u003e\n\n\u003ch3\u003eDedicated Customer Service\u003c\/h3\u003e\n\n\u003cp\u003eP\u0026amp;G features a dedicated customer service team available 24\/7, handling over \u003cstrong\u003e1 million\u003c\/strong\u003e inquiries monthly. The average response time is under \u003cstrong\u003e2 hours\u003c\/strong\u003e, contributing to a customer satisfaction rate of \u003cstrong\u003e90%\u003c\/strong\u003e. With a focus on resolution, P\u0026amp;G’s customer service has helped achieve a \u003cstrong\u003e20%\u003c\/strong\u003e decline in customer churn rates over the past year.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Relationship Element\u003c\/th\u003e\n        \u003cth\u003eKey Metrics\u003c\/th\u003e\n        \u003cth\u003eImpact on Sales\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eFeedback Systems\u003c\/td\u003e\n        \u003ctd\u003eSatisfaction Rate: 70%\u003c\/td\u003e\n        \u003ctd\u003eRetention Improvement: 15%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLoyalty Programs\u003c\/td\u003e\n        \u003ctd\u003eActive Members: 10 million\u003c\/td\u003e\n        \u003ctd\u003eRepeat Purchase Increase: 25%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eEducational Initiatives\u003c\/td\u003e\n        \u003ctd\u003eAnnual Investment: $100 million\u003c\/td\u003e\n        \u003ctd\u003eTrust Increase: 65%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDedicated Customer Service\u003c\/td\u003e\n        \u003ctd\u003eInquiries Monthly: 1 million\u003c\/td\u003e\n        \u003ctd\u003eSatisfaction Rate: 90%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese customer relationship strategies form a critical part of Procter \u0026amp; Gamble Health Limited’s business model, driving customer engagement and supporting revenue growth through enhanced customer loyalty and satisfaction.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eProcter \u0026amp; Gamble Health Limited - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eProcter \u0026amp; Gamble Health Limited utilizes a multi-faceted approach to connect with customers and deliver its value proposition. This approach includes various channels that address the diverse needs of their target market.\u003c\/p\u003e\n\n\u003ch3\u003ePharmacies and Drugstores\u003c\/h3\u003e\n\u003cp\u003ePharmacies and drugstores remain one of the primary channels for Procter \u0026amp; Gamble Health Limited. In 2022, the global pharmacy and drugstore market was valued at approximately \u003cstrong\u003e$1.2 trillion\u003c\/strong\u003e. P\u0026amp;G's health segment products are distributed through major chains like CVS Health, Walgreens, and Rite Aid.\u003c\/p\u003e\n\u003cp\u003eThe strategic partnership with these chains allows P\u0026amp;G to leverage their extensive reach, providing access to over \u003cstrong\u003e40,000\u003c\/strong\u003e retail pharmacy locations across the U.S. alone. Such accessibility is crucial for consumer trust and brand loyalty.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003cp\u003eP\u0026amp;G maintains a robust direct sales force that plays a pivotal role in marketing and selling health products. This segment accounted for approximately \u003cstrong\u003e15%\u003c\/strong\u003e of P\u0026amp;G's total revenue in fiscal year 2023, indicating its significance in the overall business model.\u003c\/p\u003e\n\u003cp\u003eThe direct sales force focuses on healthcare professionals, providing them with product samples and detailed information to drive recommendations and repeat purchases. With approximately \u003cstrong\u003e2,500\u003c\/strong\u003e direct sales representatives, P\u0026amp;G effectively covers key regions worldwide.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Retail Platforms\u003c\/h3\u003e\n\u003cp\u003eOnline retail has seen significant growth, particularly post-pandemic. P\u0026amp;G's health products were available on leading e-commerce platforms like Amazon, Walmart.com, and specialized health sites. In 2022, P\u0026amp;G's e-commerce sales reached nearly \u003cstrong\u003e$7 billion\u003c\/strong\u003e, comprising about \u003cstrong\u003e25%\u003c\/strong\u003e of its total sales.\u003c\/p\u003e\n\u003cp\u003eMoreover, P\u0026amp;G has invested in digital marketing strategies to enhance online visibility and drive traffic to its product pages. A strong data analytics framework allows P\u0026amp;G to refine customer targeting on these platforms.\u003c\/p\u003e\n\n\u003ch3\u003eMedical Conferences\u003c\/h3\u003e\n\u003cp\u003eProcter \u0026amp; Gamble Health Limited participates in numerous medical conferences each year, a channel for direct engagement with healthcare professionals and stakeholders. In 2023 alone, P\u0026amp;G attended over \u003cstrong\u003e30\u003c\/strong\u003e major conferences globally, bolstering its brand presence and networking opportunities.\u003c\/p\u003e\n\u003cp\u003eThese events enable P\u0026amp;G to present its latest research, engage with industry leaders, and gather valuable feedback from medical experts. The participation in such conferences often leads to increased product advocacy and clinical endorsements.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth\u003eChannel\u003c\/th\u003e\n      \u003cth\u003eKey Statistics\u003c\/th\u003e\n      \u003cth\u003eMarket Value\/Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n  \u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003ePharmacies and Drugstores\u003c\/td\u003e\n      \u003ctd\u003e$1.2 trillion global market\u003c\/td\u003e\n      \u003ctd\u003eAccess to over 40,000 locations\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eDirect Sales Force\u003c\/td\u003e\n      \u003ctd\u003e15% of total revenue in FY 2023\u003c\/td\u003e\n      \u003ctd\u003eApproximately 2,500 representatives\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eOnline Retail Platforms\u003c\/td\u003e\n      \u003ctd\u003e$7 billion in e-commerce sales\u003c\/td\u003e\n      \u003ctd\u003e25% of total sales\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eMedical Conferences\u003c\/td\u003e\n      \u003ctd\u003eParticipated in over 30 conferences in 2023\u003c\/td\u003e\n      \u003ctd\u003eIncreased product endorsements\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eProcter \u0026amp; Gamble Health Limited - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eProcter \u0026amp; Gamble Health Limited serves a diverse range of customer segments, effectively tailoring its offerings to meet specific needs across the healthcare market. Below are the key customer segments identified within the company's business model.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Providers\u003c\/h3\u003e\n\u003cp\u003eHealthcare providers include hospitals, clinics, and medical professionals who require quality health products for their patients. Procter \u0026amp; Gamble Health Limited engages with this segment by supplying healthcare essentials that support treatment and care. The global healthcare market reached approximately \u003cstrong\u003e$8.45 trillion\u003c\/strong\u003e in 2020 and is projected to grow at a CAGR of \u003cstrong\u003e7.9%\u003c\/strong\u003e from 2021 to 2028.\u003c\/p\u003e\n\n\u003ch3\u003eIndividual Consumers\u003c\/h3\u003e\n\u003cp\u003eIndividual consumers represent a significant portion of Procter \u0026amp; Gamble Health Limited's customer base. The company's health products cater to personal well-being, hygiene, and preventative care. According to market analysis, the global health and wellness market was valued at \u003cstrong\u003e$4.2 trillion\u003c\/strong\u003e in 2021, with a forecasted growth rate of \u003cstrong\u003e5.7%\u003c\/strong\u003e annually through 2028.\u003c\/p\u003e\n\n\u003ch3\u003ePharmacies and Retailers\u003c\/h3\u003e\n\u003cp\u003ePharmacies and retail chains are critical distribution partners for Procter \u0026amp; Gamble Health Limited's products. This segment includes large pharmacy chains such as Walgreens and CVS, as well as global retailers like Walmart and Carrefour. The retail pharmacy market was valued at around \u003cstrong\u003e$564.1 billion\u003c\/strong\u003e in 2020, with projections indicating it will grow to approximately \u003cstrong\u003e$738.4 billion\u003c\/strong\u003e by 2028, at a CAGR of \u003cstrong\u003e3.8%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eChronic Disease Patients\u003c\/h3\u003e\n\u003cp\u003eChronic disease patients require ongoing health management solutions, which Procter \u0026amp; Gamble Health Limited provides through specialized products. The prevalence of chronic diseases is rising, with the World Health Organization stating that chronic diseases account for \u003cstrong\u003e71%\u003c\/strong\u003e of all deaths globally. The global chronic disease management market was valued at around \u003cstrong\u003e$7.33 billion\u003c\/strong\u003e in 2021, expected to reach \u003cstrong\u003e$23.14 billion\u003c\/strong\u003e by 2028, growing at a CAGR of \u003cstrong\u003e18.1%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Segment\u003c\/th\u003e\n        \u003cth\u003eMarket Size (2021)\u003c\/th\u003e\n        \u003cth\u003eProjected Growth Rate (CAGR)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n        \u003ctd\u003e$8.45 trillion\u003c\/td\u003e\n        \u003ctd\u003e7.9%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eIndividual Consumers\u003c\/td\u003e\n        \u003ctd\u003e$4.2 trillion\u003c\/td\u003e\n        \u003ctd\u003e5.7%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmacies and Retailers\u003c\/td\u003e\n        \u003ctd\u003e$564.1 billion\u003c\/td\u003e\n        \u003ctd\u003e3.8%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eChronic Disease Patients\u003c\/td\u003e\n        \u003ctd\u003e$7.33 billion\u003c\/td\u003e\n        \u003ctd\u003e18.1%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis diverse segmentation allows Procter \u0026amp; Gamble Health Limited to effectively address the varied needs of its consumers, positioning the company for sustained growth across multiple markets.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eProcter \u0026amp; Gamble Health Limited - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003ch3\u003eR\u0026amp;D Expenses\u003c\/h3\u003e\n\u003cp\u003eProcter \u0026amp; Gamble (P\u0026amp;G) invests approximately \u003cstrong\u003e$1.8 billion\u003c\/strong\u003e annually in research and development. This amount represents about \u003cstrong\u003e2.7%\u003c\/strong\u003e of their total revenue. The focus of these investments includes innovation in existing products and development of new health-related products.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Costs\u003c\/h3\u003e\n\u003cp\u003eThe manufacturing costs for P\u0026amp;G Health Limited account for about \u003cstrong\u003e60%\u003c\/strong\u003e of their total operating expenses. In 2022, total manufacturing costs were reported at approximately \u003cstrong\u003e$12 billion\u003c\/strong\u003e, affected by rising raw material prices and increased labor costs.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Advertising\u003c\/h3\u003e\n\u003cp\u003eMarketing and advertising expenses for P\u0026amp;G are significant, amounting to roughly \u003cstrong\u003e$8.9 billion\u003c\/strong\u003e in the fiscal year 2022. This expenditure represents about \u003cstrong\u003e12.8%\u003c\/strong\u003e of total sales, with a significant portion allocated to digital marketing campaigns and brand awareness initiatives.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Logistics\u003c\/h3\u003e\n\u003cp\u003eP\u0026amp;G's distribution and logistics expenses tallied around \u003cstrong\u003e$5.1 billion\u003c\/strong\u003e in 2022. This encompasses transportation, warehousing, and inventory management costs. The logistics cost constitutes approximately \u003cstrong\u003e7.5%\u003c\/strong\u003e of the overall revenue, reflecting the challenges faced in supply chain efficiency and global distribution networks.\u003c\/p\u003e\n\n\u003ch3\u003eCost Structure Overview\u003c\/h3\u003e\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Type\u003c\/th\u003e\n        \u003cth\u003eAnnual Amount\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n        \u003ctd\u003e$1.8 billion\u003c\/td\u003e\n        \u003ctd\u003e2.7%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n        \u003ctd\u003e$12 billion\u003c\/td\u003e\n        \u003ctd\u003e60%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing and Advertising\u003c\/td\u003e\n        \u003ctd\u003e$8.9 billion\u003c\/td\u003e\n        \u003ctd\u003e12.8%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistribution Logistics\u003c\/td\u003e\n        \u003ctd\u003e$5.1 billion\u003c\/td\u003e\n        \u003ctd\u003e7.5%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eProcter \u0026amp; Gamble Health Limited - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003cp\u003eProcter \u0026amp; Gamble Health Limited generates its primary revenue through product sales across various categories, including over-the-counter medications, health supplements, and personal care products. For the fiscal year 2022, the company's total revenue reached approximately \u003cstrong\u003e€76.1 billion\u003c\/strong\u003e, with health and wellness products making up a significant portion of this figure.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Deals\u003c\/h3\u003e\n\u003cp\u003eLicensing represents an important revenue stream for Procter \u0026amp; Gamble Health Limited. The company engages in strategic partnerships that allow other entities to use its brand names and technologies. In recent years, P\u0026amp;G has expanded its licensing agreements, which accounted for around \u003cstrong\u003e€2.1 billion\u003c\/strong\u003e in revenue in the last fiscal year.\u003c\/p\u003e\n\n\u003ch3\u003eConsultancy Services\u003c\/h3\u003e\n\u003cp\u003eProcter \u0026amp; Gamble Health Limited also leverages its expertise in product development and marketing through consultancy services. This division focuses on offering advisory services to small and medium-sized enterprises within the health sector. In fiscal year 2022, consultancy services generated approximately \u003cstrong\u003e€500 million\u003c\/strong\u003e in revenue.\u003c\/p\u003e\n\n\u003ch3\u003eSubscription Models\u003c\/h3\u003e\n\u003cp\u003eThe company has initiated subscription models that cater to consumers who prefer regular deliveries of health products. The subscription service has shown promising growth, contributing about \u003cstrong\u003e€750 million\u003c\/strong\u003e in revenue for the year, indicating a shift towards recurring revenue streams and customer loyalty.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eRevenue Stream\u003c\/th\u003e\n        \u003cth\u003eFiscal Year 2022 Revenue (€)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduct Sales\u003c\/td\u003e\n        \u003ctd\u003e€76.1 billion\u003c\/td\u003e\n        \u003ctd\u003e93.6%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLicensing Deals\u003c\/td\u003e\n        \u003ctd\u003e€2.1 billion\u003c\/td\u003e\n        \u003ctd\u003e2.6%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eConsultancy Services\u003c\/td\u003e\n        \u003ctd\u003e€500 million\u003c\/td\u003e\n        \u003ctd\u003e0.6%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSubscription Models\u003c\/td\u003e\n        \u003ctd\u003e€750 million\u003c\/td\u003e\n        \u003ctd\u003e0.9%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45756364226709,"sku":"pghlns-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/pghlns-business-model-canvas.png?v=1739173440","url":"https:\/\/dcf-model.com\/products\/pghlns-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}